Hodgkin Lymphoma in People Living with HIV
Department of Hematology, Institute Català d’Oncologia-Germans Trias i Pujol Hospital, Carretera de Canyet s/n, 08916 Barcelona, Spain
Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain
Departament de Medicina, Can Ruti Campus, Unitat Docent Germans Trias i Pujol, Universitat Autònoma de Barcelona, 08916 Badalona, Spain
Fundació Lluita Contra la Sida, Infectious Diseases Department, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
Department of Pathology, Germans Trias i Pujol Hospital, 08916 Badalona, Spain
Author to whom correspondence should be addressed.
Academic Editor: David Wong
Received: 31 July 2021
Revised: 20 August 2021
Accepted: 25 August 2021
Published: 29 August 2021
Hodgkin lymphoma (HL) is a non-AIDS defining neoplasm, but people living with HIV (PLWH) have between a 5- and 26-fold higher risk of developing it than the general population. Epstein-Barr virus is present in almost all HIV-related HL cases, and plays an important role in its etiopathogenesis. Despite the aggressive characteristics, the prognosis of HL affecting PLWH is similar to that of the general population if patients are treated following the same recommendations. Administration of cART concomitantly with chemotherapy is highly recommended. However, this combination may be challenging due to drug–drug interactions and overlapping toxicity. Thus, interdisciplinary collaboration between hemato-oncologists and HIV specialists is crucial for the optimal treatment of both lymphoma and HIV infection.